IMMX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

IMMX ▲ +3.81% at T+5d

LONG call ✓ call won +3.81% · α vs SPY +1.96% · entry $8.67 → $9.00

Next anchor: T+20d in 12d

Currently $8.24 · -4.96% from $8.67 entry

Entry anchored
May 21, 2026
via day open

T+1d

+1.27%

call +1.27% · α +0.82%

$8.78

settled 19d ago

T+5d

+3.81%

call +3.81% · α +1.96%

$9.00

settled 12d ago

T+20d

—

call — · α —

—

in 12d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Immix Biopharma announced that all four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have converted to complete response (CR), boosting the NEXICART-2 CR rate to 95% (19/20). All CRs were reached within 1 year, with no relapses observed. All subsequently enrolled patients with available MRD results are MRD-negative at one month. These results support initiating a randomized Phase 3 trial in newly diagnosed AL Amyloidosis. Given early-stage biotech status and potentially registrational data, this is a bullish catalyst for IMMX.

Actionable Insight

This press release provides a clear positive data update that strengthens the probability of success for NXC-201. The next catalyst is the September 2026 update, with a more significant milestone in March 2027 (1-year follow-up / BLA submission). Traders should watch for potential near-term price momentum and any subsequent financing or partnership announcements. Given the small-cap biotech profile, volatility is expected.

Key Facts

NEXICART-2 CR rate is now 95% (19/20 patients)
All four MRD-negative patients from ASH 2025 converted to CR
All CRs reached within 1 year of follow-up post-dosing; no relapses to date
All subsequently enrolled patients with MRD data are MRD-negative at one month
Next NEXICART-2 update expected late September 2026
Company expects 1-year follow-up data by end of March 2027 to drive BLA submission and commercial launch
NXC-201 has Breakthrough Therapy Designation, RMAT, and Orphan Drug Designation from FDA/EMA
Estimated U.S. relapsed/refractory AL Amyloidosis patient population ~38,500 in 2026, market expected to reach $6B in 2025

Financial Impact

Potential multi-blockbuster market in a $6B+ indication; early-stage biotech with no current revenue, but a 95% CR rate in a heavily pretreated population represents strong efficacy that could support accelerated approval and eventual commercial launch.

revenuecatalystpipeline value

Risk Factors

Phase 3 trial results may not confirm Phase 2 efficacy
Regulatory approval not guaranteed despite BTD/RMAT designations
Cash runway may require additional financing before commercial launch
Competitive landscape includes other BCMA-targeted CAR-T therapies
Risk of manufacturing or safety issues as trial expands

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3299108

2 reports for IMMX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for IMMX — sortable, filterable
	Type				Now
May 21, 2026 19d ago	8-K BEARISH ★ 7/10	$8.78 $9.22	▼ −5.01%	▼ −3.35%	$8.24 (+6.15%)
May 21, 2026 20d ago	Press Release BULLISH ★ 8/10	$8.67 $9.00	▲ +3.81%	▲ +1.96%	$8.24 (−4.96%)

US Market Status

Market Open — Closes in 1h 5m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access